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Background: Continuous	 levodopa-	carbidopa	 intestinal	 gel	 (LCIG)	 diminishes	 daily	
“off”	 time	 and	 dyskinesia	 in	 patients	 with	 advanced	 Parkinson′s	 disease	 (PD).	
Complications are common with percutaneous endoscopic gastrostomy with a jejunal 
extension	tube	(PEG-	J).
Aim of the Study: To	report	the	clinical	outcome	of	LCIG	in	patients	with	advanced	PD	
in	the	years	2006–2014	at	Helsinki	University	Hospital.
Patients and Methods: Levodopa-	carbidopa	intestinal	gel	treatment	started	following	
PEG-	J	placement	in	patients	with	advanced	PD	after	successful	in-	hospital	LCIG	trial	
with	a	nasojejunal	 tube.	Demographics,	PEG-	J	procedures,	discontinuation	of	LCIG,	
complications and mortality were retrospectively analyzed.
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1  | INTRODUCTION
Patients	 with	 advanced	 Parkinson’s	 disease	 (PD)	 suffer	 from	 daily	
motor fluctuations and dyskinesia. “On” time means periods of good 
motor	control	with	no	disturbing	dyskinesia,	while	 “off”	 time	 is	peri-
ods of stiffness and poor mobility. Ideal medication reduces “off” time 





of oral levodopa and individual variation of gastric emptying in PD pa-
tients cause daily fluctuations in levodopa plasma concentration. Deep 
brain	stimulation	(DBS)	(Deep	Brain	Stimulation	for	Parkinson’s	Disease	
Study,	Group,	2001),	apomorphine	infusion	(Trenkwalder	et	al.,	2015)	
and	 continuous	 infusion	 of	 levodopa-	carbidopa	 intestinal	 gel	 (LCIG)	
(Nilsson,	Nyholm,	&	Aquilonius,	2001)	are	device-	aided	therapies	that	
can	diminish	“off”	-	time	and	dyskinesia	in	advanced	PD.	DBS,	LCIG	and	





of 20 mg/ml is administered via a portable pump that is connected to 
the	PEG-	J,	a	percutaneous	endoscopic	gastrostomy	(PEG)	with	a	thin-
ner	inner	J-	tube	placed	in	the	proximal	 jejunum.	LCIG	treatment	en-
sures continuous dopaminergic stimulation and it significantly reduces 
daily motor fluctuations and dyskinesia compared to oral levodopa 
(Olanow	 et	al.,	 2014).	However,	 complications	with	 the	 tube	 or	 the	
pump	are	common,	presenting	in	40%–96%	of	patients	(Devos,	2009;	
Fernandez	 et	al.,	 2013,	 2015;	 Nyholm	 et	al.,	 2008;	 Pickut,	 van	 der	
Linden,	Dethy,	Van	De	Maele,	&	de	Beyl,	2014).
The aim of the present study was to analyze the outcome of long- 
term	LCIG	treatment	in	advanced	PD,	paying	special	attention	to	com-
plications and discontinuation of the treatment in the clinical setting.
2  | PATIENTS AND METHODS
Altogether,	60	patients	with	advanced	PD	received	LCIG	therapy	at	
Helsinki	University	Hospital	between	2006	and	2014.	A	neurologist	
selected	 candidates	 for	 LCIG	 treatment	 i.e.,	 patients	 who	 reported	
substantial daily motor fluctuations and dyskinesia that could not 
be	sufficiently	controlled	with	oral	PD	medication.	Severe	dementia,	














scopic and fluoroscopic control by gastroenterologic surgeons in the 
endoscopic	 unit	 using	 the	 pull-	through	 method	 (Gauderer,	 Ponsky,	







passed	 to	 the	duodenum,	 the	balloon	was	 retrieved	and	 the	 J	 tube	








high- dose dopamine agonists with positive clinical response. The 
morning	 bolus	 was	 followed	 by	 a	 continuous	 infusion.	 Additional	
doses were administered by the patient when they felt they were 
entering	an	“off”	phase.	Usually,	infusion	lasted	16	hr,	supplemented	
with a sustained- release oral dose of levodopa for the night. If nec-
essary,	night	infusion	was	applied,	with	the	infusion	rate	being	about	
40%–60%	 less	 than	 infusion	 during	 the	 day.	 Control	 phone	 calls	
were	planned	 for	2–4	weeks	 after	 and	 control	 visits	 for	6	months	
after	initiation	of	LCIG	for	clinical	evaluation	in	the	outpatient	clinic.	
The patients were advised to gradually increase the daily infusion 
if several extra doses had to be taken daily. In cases of inner tube 
problems,	the	patients	were	advised	to	administer	LCIG	via	PEG	to	
the gastric space or to restart oral medication. If an infusion prob-
lem	occurred,	a	scheduled	admission	to	the	neurological	ward	was	
arranged,	with	 a	 subsequent	 endoscopic	procedure	 to	 correct	 the	
tube problem.
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Hoehn	and	Yahr	scale	assessment,	neurosurgical	contraindications	
(coagulopathy,	 cognitive	 impairment).	 Also	 daily	 hours	 on	 LCIG,	
LCIG	doses	after	6	months,	and	any	additional	oral	medication	data	
were	collected.	At	the	end	of	the	follow-	up	in	November	2015,	in-
formation about weight loss (weight change as a percentage during 
follow-	up),	living	conditions	and	discontinuation	of	the	LCIG	treat-
ment	was	gathered.	The	number	of	contacts	with	the	stoma	nurse,	
data	of	PEG-	J	 related	 (tube	occlusion,	accidental	 removal	of	 inner	
tube,	dislocation	of	the	inner	tube	backwards	into	the	stomach,	tube	
breakage),	 peristomal	 (stoma	 leakage,	 granulation	 tissue	 around	
stoma,	 skin	excoriation,	 abscess	or	 infection,	PEG	 tube	hat	buried	
in	gastric	wall,	 i.e.,	buried	bumper	syndrome	 (BBS)),	or	other	 (≥5%	
weight	 loss,	 gastric	 ulceration	 caused	 by	 inner	 tube,	 neurological)	





The study was approved by the hospital ethics committee. Data 




The results are reported as means and standard deviation (SD).	The	
significance of differences in categorical data was determined using 
Fisher’s	exact	test.	The	Mann–Whitney	U test was used to discover 
the	 differences	 in	 continuous	 variables.	 A	 level	 of	 p < .05	 was	 re-












daily	dose	 (LEDD)	of	1,266	 (441)	mg.	Ten	patients	 (17%)	were	 tak-
ing	only	levodopa,	18	(31%)	were	taking	two	drugs	and	30	(52%)	had	
three	 or	more	 different	 drugs	 daily.	 An	MMSE	 test	was	 performed	
on	48	patients	prior	to	LCIG	treatment.	The	mean	MMSE	score	was	































In sheltered housing with assistance 4	(7%)
Walker as mobility aid 15	(25%)
Wheelchair or crutches as mobility aid 6	(11%)
PD,	 Parkinson’s	 disease;	 LCIG,	 levodopa-	carbidopa	 intestinal	 gel;	 ASA,	











PEG-	J:	Boston® 20 Fr 9	(15%)
Inner tube in the descending or transverse duodenum 6	(10%)
Inner tube in the ligament of Treitz 54	(90%)
PEG-	J,	percutaneous	endoscopic	gastrostomy	with	jejunal	tube;	SD,	stand-
ard deviation.
4 of 7  |     UDD et al.
Thirty-	two	patients	were	on	LCIG	for	more	than	2	years,	and	12	
patients	 for	 more	 than	 4	years.	 Fifty-	three	 patients	 (90%)	 felt	 that	
LCIG	 treatment	 still	 substantially	 alleviated	motor	 symptoms,	when	
questioned	at	6	months	and	beyond.
3.2 | Changes in weight, living conditions and need 
for walking devices during LCIG treatment
At	baseline,	the	mean	BMI	of	the	patients	was	24.7	(4.2)	kg/m2: only 
three	patients	(5%)	were	underweight,	31	(57%)	were	normal	weight	
and	 26	 (43%)	were	 overweight.	 At	 the	 end	 of	 the	 follow-	up,	 eight	
patients	(13%)	were	underweight,	31	(52%)	were	normal	weight	and	
21	(35%)	were	overweight.	The	weight	change	as	a	percentage	was	
−3.3%	 (10.7%)	 in	 25.7	 (23.1)	 months.	 Eighteen	 patients	 (30%)	 had	
weight	loss	of	≥5%,	and	in	12	patients	(20%),	weight	loss	was	≥10%.	
One	 patient	 had	 fatal	 weight	 loss	 despite	 discontinuation	 of	 LCIG.	
Body	CT	did	not	show	any	malignancy.	The	autopsy	failed	to	reveal	




(mainly	 sheltered	housing	with	24-	hr	assistance),	 and	 three	patients	
had intervals at home and in institutions. Nine patients originally liv-
ing	with	their	spouse	(21%)	and	four	originally	living	alone	(33%)	had	
moved to sheltered housing. The need to use a walker increased by 
40%,	 (n	=	21,	 37%)	 and	 a	wheelchair	 by	50%	 (n	=	6;	 11%),	 and	 two	
patients became bedridden.
3.3 | Discontinuation
Cognitive decline or dementia at the baseline or appearance of these 
symptoms during follow up were the most common causes of infu-
sion	 withdrawal,	 occurring	 in	 seven	 patients	 after	 27	 (25)	 months	






clinical examination showed no signs of either postural instability or 
orthostatic	hypotension.	Altogether,	after	a	mean	of	21	(21)	months,	
LCIG	was	discontinued	in	15	patients,	and	in	11	cases	the	reason	was	









patients	had	2.4	 (2.1)	 complications.	 In	30	days	after	PEG-	J,	11	pa-
tients	 (18%)	had	complication	 (six	peristomal	 infections,	one	granu-
lation,	 one	 gastric	 hematoma,	 one	 nonspecific	 infection,	 one	 knot	















Discontinuation of the treatment 8	(8%)
Procedures: n	=	96






PEG-	J,	 percutaneous	endoscopic	 gastrostomy-	jejunal	 tube;	SD,	 standard	
deviation.
aOf	15	patients	discontinuing	LCIG,	two	patients	used	the	PEG	for	nutri-
tion and it was not removed.
TABLE  4 Complications	in	60	patients	on	LCIG




















     |  5 of 7UDD et al.
occurred significantly more often in patients with cognitive decline 
(MMSE	<24),	than	in	those	without	it:	8	(73%)	vs.	12	(35%);	p	=	.034.	





died	 3.7	 and	 21.5	months	 after	 discontinuing	 LCIG,	 respectively.	
The	time	from	the	start	of	LCIG	to	death	was	26.6	(14)	months.	The	
causes of death were defined by clinical examination in four patients 
and by clinical autopsy in five patients. The immediate causes of 
death were pneumonia (n	=	4),	advanced	PD	(n	=	2),	coronary	heart	
disease or insufficiency (n	=	2)	and	pulmonary	embolism	(n	=	1).	The	





nificantly higher in those alive at the end of the follow- up than in those 
who	died	during	the	follow-	up,	at	24.3	 (4.0)	vs.	18.9	 (3.1);	p = .001. 
Four	underweight	patients	(44%)	died,	compared	to	five	patients	(8%)	
with normal weight or overweight; p = .013.
4  | DISCUSSION
Levodopa-	carbidopa	intestinal	gel	treatment	has	proved	to	be	effec-
tive in reducing levodopa- related dyskinesia and diminishing off time 
compared	to	oral	medication,	 leading	to	 improvement	 in	the	quality	
of	 life	 (Antonini,	 Yegin,	 Preda,	 Bergmann,	&	Poewe,	 2015;	 Lopiano	
et	al.,	2016;	Olanow	et	al.,	2014;	Wirdefeldt,	Odin,	&	Nyholm,	2016).	
We	present	data	on	LCIG	therapy,	focusing	on	complications.	The	ma-
jority of our patients were satisfied with the infusion during follow-
	up.	 There	were,	 however,	 numerous	 tube	 and	 stoma	 complications	
related	to	LCIG,	as	reported	previously	(Fernandez	et	al.,	2015;	Lang	
et	al.,	2016;	Nilsson	et	al.,	2001).
In	most	 of	 our	 patients,	 LEDD	was	 increased	 at	 6	months	 com-
pared	to	baseline.	The	LEDD	increase	may	be	caused	by	disease	pro-
gression.	We	had	12	patients	(20%)	with	their	LCIG	pump	running	for	




tients	with	 an	MMSE	of	28–29	were	 included	 (Epstein	et	al.,	 2016;	
Fernandez	et	al.,	2015).	In	a	French	multicentre	study	(Devos,	2009),	
50%	of	the	patients	on	LCIG	had	cognitive	disorders	suggestive	of	PD	







Several technical problems and complications increase the annual 
admission	 rate	 and	 contact	with	 the	 hospital	 (Nyholm	 et	al.,	 2008).	
Complications	with	 the	 PEG-	J	 tube	 (Devos,	 2009;	 Fernandez	 et	al.,	
2013;	Nyholm	et	al.,	2008)	are	similar	to	complications	related	to	PEG	
for	 feeding	 purposes	 (Schapiro	 &	 Edmundowicz,	 1996;	 Udd	 et	al.,	
2015).	The	risk	of	peritonitis	has	varied	between	zero	and	4%	(Devos,	
2009;	Epstein	 et	al.,	 2016;	 Lang	et	al.,	 2016;	Palhagen	et	al.,	 2016),	
and	 other	 serious	 complications	 like	 colonic	 perforations,	 gastrop-
leural	 fistula	 (Klostermann	et	al.,	2012)	and	 liver	 injury	 (Pickut	et	al.,	
2014),	 have	 also	 been	 described.	 In	 our	 material,	 we	 did	 not	 have	






times	 suffering	 from	 disorientation	 (Devos,	 2009;	 Fernandez	 et	al.,	
2013;	Nyholm	et	al.,	2008;	Pickut	et	al.,	2014).	We	did	not	find	any	
cases	of	inner	tube-	induced	duodenal	decubitus	ulcer	(Martino	et	al.,	
2016),	 or	 bezoar	 sometimes	 present	 in	 these	 patients.	 Our	 results	
showed	that	13	patients	had	a	total	of	27	tube	occlusions,	and	eight	
of	them	(61%)	had	altogether	ten	knots	in	the	inner	tube.	Previously,	
only three case reports of five patients with knotting of the inner tube 
had	been	published	(del-	Hoyo-	Francisco	et	al.,	2015;	Krones,	Zollner,	
&	Petritsch,	2012;	Nyholm	et	al.,	2008).	The	Freka® intestinal tube has 
an	angled,	C-	shaped	 tip,	and	 this	may	predispose	 the	 tube	 to	knots	
(Figure	1).	The	present	results	showing	that	removal	of	the	inner	tube	
occurs more often in patients with dementia are supported by previ-
ous	findings	(Devos,	2009).	Logically,	among	patients	with	no	demen-
tia,	the	rate	is	lower	(Epstein	et	al.,	2016;	Fernandez	et	al.,	2015).
The triangular external fixation plate of the Freka®	PEG-	J	 tube	 is	
suboptimal,	because	it	glides	along	the	PEG	tube,	allowing	the	PEG	to	
move back and forth. This movement may even predispose the patient 
F IGURE  1 Naive and knotted jejunal 
tube
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partly associated with the natural course of PD. One third of our pa-
tients	had	≥5%	weight	loss	during	the	follow-	up	with	one	fatal	weight	





Eighty percent of the patients had complications leading to mul-
tiple	 endoscopic	 procedures,	 but	 still	 90%	 were	 satisfied	 with	 the	
treatment. Some of the complications may therefore be related to the 
suboptimal	devices	and	tubes.	A	new	T-	port	was	found	to	be	well	tol-
erated,	and	it	had	a	low	number	of	tube	problems,	but	proper	clean-




patient	 is	 bedridden,	 disoriented	 and	 already	 needs	maximal	 care,	
LCIG	probably	may	not	 give	 any	 significant	 health	 benefit.	 Several	
removals of the inner tube by a patient during the treatment suggest 
that the mental condition of that patient has significantly deterio-
rated.	In	these	cases,	discontinuation	of	LCIG	should	be	individually	
considered.	Further,	several	replacements	of	the	inner	tube	increase	
the burden of already limited hospital resources. Continuous weight 
loss	can	even	be	a	fatal	complication,	and	therefore	needs	monitor-
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